anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

195,061-195,120 of 319,975

filter-aware
82
Berkeley Lights | Investor Day Presentation Deck | 91 slidesBerkeley Lights | Investor Day Presentation Deck | 91 slides · Berkeley Lights
Conference presentation Investor relations Beat · Action1 hit
83
Includes actuals for 2018-2021 and forecasts for 2022.Berkeley Lights | Investor Day Presentation Deck | 91 slides · Berkeley Lights
Conference presentation Investor relations Beat · Action1 hit
84
Berkeley Lights | Investor Day Presentation Deck | 91 slidesBerkeley Lights | Investor Day Presentation Deck | 91 slides · Berkeley Lights
Conference presentation Investor relations Beat · Action1 hit
85
The slide uses bar charts to show historical data (2018-2021) and projections (2022, 2025).Berkeley Lights | Investor Day Presentation Deck | 91 slides · Berkeley Lights
Conference presentation Investor relations Beat · Action1 hit
86
Berkeley Lights | Investor Day Presentation Deck | 91 slidesBerkeley Lights | Investor Day Presentation Deck | 91 slides · Berkeley Lights
Conference presentation Investor relations Beat · Action1 hit
87
The chart shows a 38% CAGR for partnership revenue from 2022 to 2025.Berkeley Lights | Investor Day Presentation Deck | 91 slides · Berkeley Lights
Conference presentation Investor relations Beat · Action1 hit
88
The slide uses bar charts for revenue and gross profit, and a combination bar/line chart for cash and free cash flow.Berkeley Lights | Investor Day Presentation Deck | 91 slides · Berkeley Lights
Conference presentation Investor relations Beat · Action1 hit
89
The slide combines a quadrant-based strategy overview with a waterfall bridge chart.Berkeley Lights | Investor Day Presentation Deck | 91 slides · Berkeley Lights
Conference presentation Investor relations Beat · Action1 hit
90
Berkeley Lights | Investor Day Presentation Deck | 91 slidesBerkeley Lights | Investor Day Presentation Deck | 91 slides · Berkeley Lights
Conference presentation Investor relations Beat · Action1 hit
91
Berkeley Lights | Investor Day Presentation Deck | 91 slidesBerkeley Lights | Investor Day Presentation Deck | 91 slides · Berkeley Lights
Conference presentation Investor relations Beat · Action1 hit
01
Slide 1
BioAtla | Investor Presentation Deck | 40 slidesBioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
02
BioAtla | Investor Presentation Deck | 40 slidesBioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
03
The slide uses a connected circle diagram to represent the company's key pillars.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
04
BioAtla | Investor Presentation Deck | 40 slidesBioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
05
Uses a visual comparison framework to contrast healthy cells (no binding) vs cancer cells (binding).BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
06
The slide uses a three-column layout to illustrate the versatility of the CAB platform across different therapeutic mechanisms.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · Solution1 hit
07
The slide uses a Gantt-style visualization to show the clinical stage of drug candidates.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · Solution1 hit
08
BioAtla | Investor Presentation Deck | 40 slidesBioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
09
The slide uses a structured list format to contrast the specific opportunity in UPS with the broader landscape of other sarcoma subtypes.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · Market Size1 hit
10
Includes waterfall plot for partial response and spider plot for longitudinal tumor change.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
11
The slide uses a hierarchical tree structure to map patient cohorts to their respective clinical outcomes and advancement decisions.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
12
Includes 'Number at Risk' table below the Kaplan-Meier plot.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
13
Includes specific clinical trial safety metrics (AEs, SAEs, CTCAE grades).BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
14
BioAtla | Investor Presentation Deck | 40 slidesBioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
15
The slide uses a 2x2 grid of metrics to frame the market opportunity, followed by specific target population and success threshold data.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
16
The chart displays maximum change from baseline for four distinct patient cohorts/scenarios.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
17
The slide uses a process-oriented layout to describe clinical trial phases.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
18
Data cut-off Oct 28, 2022. Includes definitions for W/D, NSQ, SQ, and response markers.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
19
Waterfall plot showing clinical response (PD, SD, PR, CR) for patients treated with BA3011.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
20
Data presented in a table format comparing BA3011 (N=13) and BA3011 + Opdivo (N=9).BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
21
BioAtla | Investor Presentation Deck | 40 slidesBioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
22
The slide uses a grid of metrics to define the addressable market and clinical success thresholds.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
23
The chart is a waterfall plot showing percentage change in tumor size for individual patients.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
24
The slide uses a 2x2 grid of metrics to frame the market problem, followed by specific target population sizing.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
25
The chart displays longitudinal data for two specific patients, showing sustained complete response.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
26
The slide uses a combination of big numbers and bulleted lists to frame the market opportunity and clinical unmet need.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
27
The slide uses a table to present clinical outcomes (PR/CR) for specific tumor types, supporting the 'first-in-class' claim.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
28
The slide uses a process-flow layout to describe clinical trial progression.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
29
BioAtla | Investor Presentation Deck | 40 slidesBioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
30
The slide uses a combination of a comparison table for clinical data and a dot plot for NHP toxicity data.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
31
The slide uses a timeline-based visualization to show dose escalation steps. RP2D = Recommended Phase 2 Dose. DLT = Dose Limiting Toxicity.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
32
BioAtla | Investor Presentation Deck | 40 slidesBioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
33
Uses a before-after-bridge style framing (problem on left, solution/results on right).BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
34
The slide uses a process flow diagram to illustrate clinical trial dose escalation cohorts.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
35
The slide uses a table-based timeline format to map specific clinical trial phases to programs and indications.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
36
The slide uses a linked-circle diagram to represent the company's key pillars.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
37
BioAtla | Investor Presentation Deck | 40 slidesBioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
38
BioAtla | Investor Presentation Deck | 40 slidesBioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
39
Includes a Kaplan-Meier survival curve and a summary table of clinical outcomes.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
40
Includes Kaplan-Meier plots with embedded data tables for two distinct patient cohorts.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
01
Slide 1
Blue Apron | Results Presentation Deck | 17 slidesBlue Apron | Results Presentation Deck | 17 slides · Blue Apron
Conference presentation Investor relations 1 hit
02
Blue Apron | Results Presentation Deck | 17 slidesBlue Apron | Results Presentation Deck | 17 slides · Blue Apron
Conference presentation Investor relations 1 hit
03
Blue Apron | Results Presentation Deck | 17 slidesBlue Apron | Results Presentation Deck | 17 slides · Blue Apron
Conference presentation Investor relations 1 hit
04
Blue Apron | Results Presentation Deck | 17 slidesBlue Apron | Results Presentation Deck | 17 slides · Blue Apron
Conference presentation Investor relations 1 hit
05
The slide uses a kitchen-themed background, likely reflecting the Blue Apron brand.Blue Apron | Results Presentation Deck | 17 slides · Blue Apron
Conference presentation Investor relations 1 hit
06
Includes detailed footnotes defining the metrics.Blue Apron | Results Presentation Deck | 17 slides · Blue Apron
Conference presentation Investor relations 1 hit
07
Blue Apron | Results Presentation Deck | 17 slidesBlue Apron | Results Presentation Deck | 17 slides · Blue Apron
Conference presentation Investor relations 1 hit
08
Blue Apron | Results Presentation Deck | 17 slidesBlue Apron | Results Presentation Deck | 17 slides · Blue Apron
Conference presentation Investor relations 1 hit
09
The chart displays a dual-axis style visualization (bars for revenue, line for customers) despite the lack of a secondary Y-axis label.Blue Apron | Results Presentation Deck | 17 slides · Blue Apron
Conference presentation Investor relations 1 hit
10
Includes YoY growth percentages for each metric and detailed footnotes defining the KPIs.Blue Apron | Results Presentation Deck | 17 slides · Blue Apron
Conference presentation Investor relations 1 hit